ATE188486T1 - Modifizierte polypeptide mit erhoehter biologischer aktivitaet - Google Patents

Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Info

Publication number
ATE188486T1
ATE188486T1 AT95912917T AT95912917T ATE188486T1 AT E188486 T1 ATE188486 T1 AT E188486T1 AT 95912917 T AT95912917 T AT 95912917T AT 95912917 T AT95912917 T AT 95912917T AT E188486 T1 ATE188486 T1 AT E188486T1
Authority
AT
Austria
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Application number
AT95912917T
Other languages
English (en)
Inventor
Arthur J Sytokowski
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Application granted granted Critical
Publication of ATE188486T1 publication Critical patent/ATE188486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95912917T 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet ATE188486T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity
PCT/US1995/003242 WO1995025746A1 (en) 1994-03-22 1995-03-15 Modified polypeptides with increased biological activity

Publications (1)

Publication Number Publication Date
ATE188486T1 true ATE188486T1 (de) 2000-01-15

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95912917T ATE188486T1 (de) 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Country Status (9)

Country Link
US (1) US5580853A (de)
EP (1) EP0751959B1 (de)
AT (1) ATE188486T1 (de)
DE (1) DE69514342T2 (de)
DK (1) DK0751959T3 (de)
ES (1) ES2143620T3 (de)
GR (1) GR3033146T3 (de)
PT (1) PT751959E (de)
WO (1) WO1995025746A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
EP0914094A4 (de) 1996-03-28 2000-03-01 Univ Illinois Materialen und verfahren zur herstellung verbesserter liposomaler mittel
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
AU2001296354A1 (en) 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
BR0206919A (pt) * 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP2261244A3 (de) 2003-04-15 2011-02-23 Glaxosmithkline LLC Humane IL-18 Substitutionsmutanten und deren Konjugate
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
ATE428727T1 (de) 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
AU2004238868B2 (en) * 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
HRP20060362A2 (en) 2004-04-23 2007-03-31 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
WO2006063055A2 (en) * 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
ES2388068T3 (es) * 2004-12-23 2012-10-08 Molmed Spa Producto de conjugación
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
ME03353B (de) 2011-03-29 2019-10-20 Immunogen Inc Herstellung von maytansinoid-antikörperkonjugaten anhand eines einstufigen verfahrens
CN103717614A (zh) 2011-08-09 2014-04-09 普罗法尔马封闭式股份公司 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
CN117658991A (zh) * 2023-12-05 2024-03-08 南昌大学 一种异型双功能交联剂及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
PT751959E (pt) 2000-06-30
ES2143620T3 (es) 2000-05-16
US5580853A (en) 1996-12-03
GR3033146T3 (en) 2000-08-31
WO1995025746A1 (en) 1995-09-28
EP0751959B1 (de) 2000-01-05
DE69514342T2 (de) 2000-11-30
DE69514342D1 (de) 2000-02-10
DK0751959T3 (da) 2000-06-26
EP0751959A1 (de) 1997-01-08

Similar Documents

Publication Publication Date Title
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
IT8812558A0 (it) Poltrona per abbronzatura
DE3582183D1 (de) Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
DK14890D0 (da) Peptider med t-hjaelpercelleaktivitet
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
FI870633A7 (fi) Tuolin istuin.
DK96787A (da) Human vaevs-plasminogenaktivator
DE3579148D1 (de) Polypeptid und polypeptidzusammensetzung.
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
FI893833A7 (fi) Rekombinant aktivator foer naturliga doedarceller.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
DE68904336D1 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
KR890015933U (ko) 회전의자
DE69019581D1 (de) Polypeptid und dieses enthaltende antibaktierelle Präparate.
DK527287D0 (da) Polypeptid med interleukin-2-aktiviteter
DE3782199D1 (de) Biologisch aktive peptide tan-866.
NO912072L (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.
IT8619477A0 (it) Sostanza ad attivita'nootropa e psicostimolante.
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.
KR850007051U (ko) 요동식 침대의자

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee